PharmaJet Partner, Scancell, Announces Phase 2 Melanoma DNA Vaccine Trial will include Needle-free Delivery
Use of PharmaJet Needle-free Injection System expands to Melanoma DNA Vaccine with Scancell phase 2 trial. Studies show improved immunogenicity.
The copyright of this article belongs to the original author/organization.
The current content only represents the author’s point of view, and has nothing to do with the position of Longbridge. The content is for investment reference only and does not constitute any investment advice. If you have any questions or suggestions about the content services provided by Longbridge, please contact: email@example.com